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  Binding affinities and fluorescence characteristics
of fluorescent-labeled benzodiazepines:
    The choice of an optimal fluorescent-labeled
ligand for benzodiazepine receptor assays
4.1 Introduction
In this Chapter, the binding affinities of fluorescent-labeled benzodiazepines will be discussed and an appropriate
ligand for the benzodiazepine fluorescence receptor assay will be selected. These discussions will be supported
by structure activity relationships derived from literature.
There are several criteria to be considered, such as the position of the label in the molecule, the type of
fluorophore and the choice of the benzodiazepine for labeling. Does the parent compound require affinity for the
benzodiazepine receptor or can a compound without affinity also be used for labeling? Besides the binding
affinities of the ligands, the fluorescence characteristics of the fluorophores also play an important role in the
selection of the best ligand.
In our work, we used calf brains for the determination of the affinity constants of the different benzodiazepine
derivatives. However, the inhibition constants of the fluorescent-labeled benzodiazepines described in the
literature, were determined with either rat or calf brains. Figure 4.1 shows the correlation between calf [1] and rat
[2] benzodiazepine receptors for the Ki-values of seven benzodiazepines. The species difference in the receptor
binding of benzodiazepines appears to be small, which has also been observed for human and rat brains [3], so
that a comparison of our results with Ki-values from literature can be made.
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Figure 4.1 Correlation between the log Ki values (in nM) of several benzodiazepines determined with calf
brain homogenate (from ref. [1]) or with rat brain homogenates (from ref. [2]) (r = 0.90).
4.2 Binding affinities
1,4-Benzodiazepines
In Chapter 2 the affinity constants (Ki) of several fluorescent-labeled 1,4-benzodiazepines were described,
including the ligands synthesized by our group as well as the ligands described in the literature (Table 4.1). The
basic structures of 1,4-benzodiazepines and 1,2-annelated 1,4-benzodiazepines are shown in Figure 4.2. Detailed
structures can be found in the Appendix.
Oxazepam and lormetazepam were labeled at the 3-position after coupling of succinic anhydride to the OH-groups
yielding oxazepam hemisuccinate and lormetazepam hemisuccinate, respectively. The reactive carboxylgroup
obtained in this way was then labeled with the fluorophore 4-bromomethyl-7-methoxycoumarin, which gave the
fluorescent-labeled benzodiazepines Mmc-O-CO-(CH2)2-CO-oxazepam and Mmc-O-CO-(CH2)2-CO-lormetaze-pam,
respectively. The labeling in position 3 resulted in a 40-60 fold decrease in binding affinities towards the
benzodiazepine receptor, for oxazepam from 16.7 nM to more than 1 µM and for lormetazepam from 1.2 to 114 nM.
This loss in affinity for labeling at the 3-position has also been described by others [4-6].




































   67 nM
   51 nM
 132 nM
 163 nM
   74 nM
 8.6 nM
 0.6 nM







The effect of labeling at the 7-position was examined by using 7-aminonitrazepam (Ro5-3072), a metabolite of
nitrazepam. This metabolite has less affinity towards the receptor, 470 nM as compared to 7.4 nM for nitrazepam
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itself, but Ro5-3072 has a reactive amino-group at the 7-position. This group was labeled with dansyl chloride to





























Figure 4.2 Basic structures of 1,4-benzodiazepines and 1,2-annelated 1,4- benzodiazepines.
Actually, the binding affinity of > 1 µM was even lower than of 7-aminonitrazepam. Haefely et al. [7] suggested
that benzodiazepines need electronegative substituents at position 7, such as -Cl, -Br or -NO2, in order to have
suitable binding affinity. This has also been described by Sternbach et al. [5]. They also found that an increase in
size of an alkyl substituent at position 7 caused a lower binding potency and that substituents with a sulfone-
group, which have strong electron-withdrawing properties, showed a decrease in affinity as well. These findings
are in line with our observation that 7-aminonitrazepam has no affinity towards the benzodiazepine receptor, since
labeling with dansyl chloride implies the introduction of a large substituent with a sulfone-group. The use of
another fluorophore, without a sulfone-group, may partly limit this loss in binding affinity. Since all fluorophores
are relatively bulky substituents, high affinity towards the receptor is not expected after labeling at the 7-position.
Therefore, we believe that labeling at either the 3- or the 7-position does not result in a product with a sufficiently
high affinity towards the benzodiazepine receptor irrespective of the choice of the fluorophore.
Position 1 has been successfully labeled by several researchers. They used didesethylflurazepam (Ro7-1986), a
metabolite of flurazepam, which contains a primary amino-group [8-10]. Didesethylflurazepam itself has a relatively
high affinity towards the benzodiazepine receptor (Ki=4.9 nM), whereas the parent compound flurazepam has a Ki
of 10.4 nM. Haefely et al. [7] described that relatively long side chains on the nitrogen 1-position induced only a
moderate decrease in affinity. This makes didesethylflurazepam a suitable precursor for labeling.
Didesethylflurazepam has also been used as ligand in affinity chromatography, by attaching it to agarose through
a spacer chain [11]. Different fluorophores were coupled to the amino-group of didesethylflurazepam. Takeuchi
and Rechnitz [8] used the coumarin 7-amino-4-methylcoumarin-3-acetic acid N-hydroxysuccinimide esther (NHS-
AMCA) for labeling. The resulting product, AMCA-Ro7-1986, had a Ki of 8.6 nM. Labeling of Ro7-1986 with
5-carboxylfluorescein N-hydroxysuccinimide ester, as described by McCabe et al. [9], resulted in a fluorescein
derivative of Ro7-1986 with a Ki of 63 nM. Velazquez et al. [10] used 4-fluoro-7-nitrobenz-2-oxa-1,3-diazole (NBD-
F), which resulted in NBD-Ro7-1986, with a Ki-value of 79 nM. In our labeling experiments of Ro7-1986 with
various fluorophores, we found the following Ki-values: a similar Ki-value for NBD-Ro7-1986, namely 51 nM, a Ki-
value of 67 nM for
Bodipy
®
FL-Ro7-1986 and a Ki-value of 167 nM for the dansyl-derivative.
These results show that labeling of the 1-position of 1,4-benzodiazepines can yield useful products dependent on
the choice of the fluorophore. Sternbach at al. [12] observed that precursors with a terminal dialkylamino-group
on the side chain on the 1-position provided compounds with a higher affinity than compounds based on
precursors with a terminal heterocyclic substituent. The lower affinity of the latter can be caused by steric
hindrance of the heterocyclic substituents. This may be reduced by enlarging the distance between the amino-
group and the substituents. Velazquez et al. [10] incorporated two spacers with different lengths between the
parent benzodiazepine Ro7-1986 and the fluorophore NBD. However, the spacers reduced the binding affinity, in
that the incorporation of -(CH2)2-CO- resulted in a Ki of 132 nM and the incorporation of -(CH2)5-CO- in a Ki of 163
nM. This implies that the small loss in affinity by coupling a fluorophore to the benzodiazepine derivative Ro7-




Besides the 1,4-benzodiazepine derivative Ro7-1986, benzodiazepines of other classes, such as the 1,2-annelated
benzodiazepines, have also been used for fluorescent labeling. The affinity constants of some fluorescent-labeled
1,2-annelated 1,4-benzodiazepines are reported in Table 4.1. Takeuchi et al. successfully used 1012-S, a
triazolobenzodiazepine, for labeling, either with biotin [13,14] or with a europium chelating reagent, N-(p-
isothiocyanato-benzyl)diethylenetri-amine-N,N',N'',N''-tetraacetic acid [15,16]. The latter label was measured by
time resolved fluorescence. The affinity constants of these compounds were 0.31 and 1.2 nM, respectively,
whereas the parent compound 1012-S had a Ki of 0.4 nM [17]. The biotinylated 1021-S was used as ligand in a
non-isotopic receptor assay for benzodiazepines. Velazquez et al. [10] also labeled 1012-S with the fluorophore
NBD-F. However, they observed an affinity constant for NBD-1012-S of 85 nM, about 100-fold higher than the
compounds of the group of Takeuchi.
An other 1,2-annelated 1,4-benzodiazepine, which has been used several times for labeling, is the
imidazobenzodiazepine desethylflumazenil (Ro15-3890), a metabolite of the benzodiazepine antagonist flumazenil
(Ro15-1788). Desethylflumazenil itself has no affinity towards the benzodiazepine receptor (Ki > 1 µM), whereas
flumazenil has a Ki-value of 0.6 nM. However, Ro15-3890 contains a reactive group, a carboxyl group. Direct
labeling of this carboxyl group with 4-bromomethyl-7-methoxycoumarin resulted in a compound with an affinity of
121 nM, which is unacceptable for use as a sensitive ligand in the benzodiazepine fluorescence receptor assay.
Flumazenil contains a terminal ethyl chain at the carboxyl group. Therefore, a spacer of three carbon atoms was
introduced between Ro15-3890 and the fluorophore. With this spacer, the affinity was increased to 6.5 nM, with
Mmc- as fluorophore [18]. McCabe et al. [9] and Havunjian et al. [19] also labeled desethylflumazenil via a spacer.
They used a different spacer than we did, with a terminal amino-group instead of our carboxyl-group, but the
resulting alkyl chain was of the same length, namely three C-atoms. Havunjian et al. used NBD as fluorophore and
observed a Ki of 5.7 nM, which is of the same order as for our MmC-O-CO-(CH2)3-Ro15-3890. However, McCabe et
al. used fluorescein and their ligand had a 10-fold lower affinity (Ki was 63 nM). This shows that the choice of the
fluorophore has a marked but rather unpredictable effect on the binding affinity.
Several structure-activity relationship studies have been performed to assess which positions of the
imidazobenzodiazepines are involved in the binding to the benzodiazepine receptor.
Table 4.2 Affinity of imidazobenzodiazepine-3-carboxylic acid derivatives for the benzodiazepine receptor
[20].

































Table 4.2 shows the general structure and some affinity constants of some 3-substituted imidazobenzodiazepines
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possesses a fluorine atom at this position which increases the affinity, the influence of the substituents can still
be examined. The length of the alkyl chain as well as the branching appear to play a role in that the length has a
negative effect on the affinity and branching a positive one. According to Fryer [21], the interaction of
imidazobenzodiazepines also involves hydrogen bonding interactions at the imidazole nitrogen, pi1, as well the
ester carbonyl oxygen, pi2, at the receptor site. Ananthan et al. [22] found that compounds possessing carbamate,
acylamino, sulfonyl, oxazolinyl and benzoxazolyl functions have low affinities for the benzodiazepine receptors.
This also indicates that favourable hydrogen bonding and steric interactions in regions surrounding the pi1 and pi2
proton-accepting sites are important for high affinity binding of the imidazobenzodiazepines. A model for the
interaction of imidazobenzodiazepine-3-carboxylic esters was developed by Ananthan et al. [22] and is shown in
Figure 4.3.
The lack of affinity of Ro15-3890 itself (Ki > 1 µM [18]) is probably due to the disturbed hydrogen bonding at the pi2
proton-accepting site of the carbonyl oxygen. Mmc-Ro15-3890 still has a low affinity for the benzodiazepine
receptor (Ki = 121 nm), conceivably caused by steric hindrance.
Figure 4.3 Model for the interaction of imidazobenzodiazepine-3-carboxylic esters at the benzodiazepine
receptor site, according to Ananthan et al. (from ref. [22]).
This steric hindrance could be reduced by introducing an alkyl chain between the imidazobenzodiazepine moiety
(Ro15-3890) and the fluorophore: Ro15-3890 has been labeled with three different fluorophores, the coumarin
derivative Mmc (Ki = 6.5 nM [18]), fluorescein (Ki = 63 nM [9]) and NBD (Ki = 5.7 nM [19]), respectively.
Two spacers were used; both had the same alkyl length, namely propyl, but the terminal groups were different. In
our work, a terminal carboxyl-group was used for the labeling of Mmc, whereas McCabe et al. [9] and Havunjian et
al. [19] used a terminal amino-group for the labeling with fluorescein and NBD, respectively.
It should be observed that the choice of the fluorophore may also affect the affinity. The fluorescein derivatives
usually have a ten-fold lower affinity for the benzodiazepine receptor than the corresponding Mmc- and NBD-
derivatives. This is probably caused by steric hindrance, due to the bulkiness of fluorescein.
Furthermore, our results with Mmc-O-CO-(CH2)3-Ro15-3890 and NBD-NH-(CH2)3-Ro15-3890 also indicate that
benzodiazepine compounds without affinity for the receptor can be successfully used as precursors for labeling
and that it is not necessary to start with a precursor with a high affinity. In fact, the use of a precursor without
affinity for the benzodiazepine receptor even represents a distinct advantage: In the event that hydrolysis occurs
of the fluorescent labeled Ro15-3890 derivatives, the resulting Ro15-3890 has no affinity for the benzodiazepine
receptor. However, an eventual hydrolysis of fluorescent-labeled Ro7-1986 derivatives, such as AMCA-Ro7-1986,
 will result in a compound with an even higher affinity for the benzodiazepine receptor than the labeled
derivatives, thus causing substantial interference in the receptor assay. Therefore, we strongly prefer Ro15-3890








































































phycobiliproteins: R-Phycoerythrin:  λex = 565 nm, λem = 578 nm
B-Phycoerythrin:  λex = 545 nm, λem = 575 nm
C-Phycoerythrin:  λex = 620 nm, λem = 650 nm
Allophycocyanin: λex = 650 nm, λem = 660 nm
Figure 4.4 Structures of some fluorophores.
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4.3 Fluorescence characteristics
A wide variety of fluorophores is available for labeling of the benzodiazepines, particulary for benzodiazepines
containing a reactive amino-group. Figure 4.4 shows the structures of some fluorophores.
The selection of the most suitable fluorophore is not only dependent on the affinity of the fluorescent-labeled
ligand for the benzodiazepine receptor. First, the fluorescent-labeled ligand must be stable for longer periods of
time under various conditions. The fluorophore o-phthaladehyde (OPA), reactive to primary amines, is often used
as post-column reagent in chromatographic assays [23,24], but the resulting coupling products are unstable. Yet,
the fluorophores used in the Chapters 2 and 3, NBD-F, dansyl chloride, fluorescein, Bodipy FL and the
coumarines all yield stable products. Second, the fluorescence properties of the labeled ligand should allow
sensitive and selective detection. The excitation wavelength should preferably exceed 500 nm to minimize
autofluorescence of matrix components, such as proteins, but suitable substances are difficult to find. Fluorescein
(λex = 492 nm), rhodamine B (λex = 550 nm) and Bodipy FL (λex = 505 nm) fulfil this requirement, but the molecular sizes
of these fluorophores are also larger. This makes them less suitable as labels in fluorescent receptor assays, since
the bulkiness of these fluorophores may result in lower affinities for the benzodiazepine receptor due to steric
hindrance.
Phycobiliproteins are highly soluble fluorescent proteins which are excitated at higher wavelengths (λex ranging
from 545 to 650 nm) [25]. These conjugates belong to the most sensitive fluorescent probes available and B- and
R-phycoerythrin have been used successfully in immunoassays [26,27]. However, since they have a molecular
weight of 240,000, they are not suitable for the direct labeling of ligands in fluorescent receptor assays.
As for other fluorophores, NBD-derivatives are excited at relatively high wavelengths (λex = 468 nm), as compared
to the coumarins (Mmc: λex = 315 nm, AMCA: λex = 354 nm) and dansyl chloride (λex = 340 nm) derivatives.
An other requirement is that the fluorophore must have a high fluorescence intensity in aqueous media, since the
sensitivity of the fluorescent receptor assay is determined by the possibility to quantitate either the bound or the
free fraction of the fluorescent-labeled ligand, depending on the method. In order to assess the impact of
detectability of the fluorescent ligand, a comparison has been made with a radioreceptor assay for
benzodiazepines with radioactive-labeled flunitrazepam. [3H]flunitrazepam had a specific activity of 3.2 * 1012
Bq/mmol and amounts of 0.7 fmol could be quantitated with an accuracy of 5% (with a counting time of 5 min).
The detection limit of the fluorescent-labeled ligand is strongly dependent on the instrumentation used.
Fluorescence detectors for chromatographic purposes are usually more sensitive than static detectors.
Table 4.3 Fluorescence characteristics of fluorescent-labeled 1,4-benzodiazepines in Tris-HCl buffer (pH
7.4; 50 mM). The molar fluorescence signals of the fluorescent-labeled 1,4-benzodiazepines are
expressed relatively to the signal of 5 mM quinine sulphate in 1 N sulphuric acid (=100).
relative
fluorescence

































The sensitivity can be increased by using laser-induced fluorescence (LIF), but a disadvantage of LIF is that a
laser source can only emit light at a limited number of fixed wavelengths. The latter may not be compatible with
the fluorophore of choice in fluorescent receptor assays.
The relative fluorescence intensities of the synthesized fluorescent-labeled benzodiazepines are given in Table
4.3, together with the relative fluorescence intensities of NBD-Ro7-1986 and Bodipy FL-Ro7-1986. It is obvious
that Bodipy FL-Ro7-1986 has the highest fluorescence intensity, but the latter is not usable at the maximum
excitation and emission wavelengths (λex = 505 nm and λem = 508 nm), since the Stokes shift is only 3 nm. Rayleigh
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scattering precludes quantitation of Bodipy FL derivatives at these wavelengths. Alternatively, Bodipy FL
derivatives can be quantitated at suboptimal wavelengths, yet at the expense of fluorescence intensity.
Fluorescein derivatives are also reported to have high fluorescence intensities in aqueous media at alkaline pH.
However, the fluorescence intensities diminish with decreasing pH. Since we did not have fluorescein-Ro7-1986
and fluorescein-NH-(CH2)3-Ro15-3890 available, we were not able to measure their fluorescence intensities.
However, since these fluorescent-labeled benzodiazepines had only moderate affinities for the benzodiazepine
receptor (fluorescein-Ro7-1986 had a Ki of 74 nM and fluorescein-NH-(CH2)3-Ro15-3890 had a Ki of 63 nM), these 
compounds are not interesting as ligand in fluorescent receptor assays for benzodiazepines.
The Mmc-derivatives tested had fluorescences (relative to the fluorescence of 5 mM quinine sulphate in 1N H2SO4)
ranging from 50 to 59 in Tris-HCl buffer, pH 7.4. These values are higher than those of NBD-Ro7-1986 and the
dansyl derivatives of Ro7-1986 and Ro5-3072. Since we did not have access to the reference substance, we did
not determine the relative fluorescence of NBD-NH-(CH2)3-Ro15-3890, but we assume that it is comparable to that
of NBD-Ro7-1986. Ahnoff et al. [28] also described the low fluorescence intensity of NBD-hydroxyproline in
water, whereas it had higher intensities in organic solvents. Although NBD-NH-(CH2)3-Ro15-3890 has a higher
excitation wavelength, we consider Mmc-O-CO-(CH2)3-Ro15-3890 to be a more suitable fluorescent-ligand than
NBD-NH-(CH2)3-Ro15-3890, since the fluorescence intensities of the Mmc-derivatives is three times higher than the
fluorescence intensities of the NBD-derivatives.
4.4 Conclusions
From the results described in this Chapter, it can be concluded that there are several limitations for a labeled
ligand for use in the benzodiazepine receptor assay. To obtain affinity to the receptor, both the position of
labeling, the molecular size (or bulkiness) of the fluorophore and the use of a spacer are important factors.
Regarding to the position of labeling, there are two (or three when 1021-S is also taken in account) benzodiazepine
compounds which can be used as precursor. For the 1,4-benzodia-zepines, only labeling at position 1 will not
disturb the binding affinity. The precursor of choice is didesethylflurazepam (Ro7-1986), which has a primary
amino group. The size of the fluorophore has an enormous influence on the binding affinity, due to steric
hindrance. Therefore, small fluorophores, such as coumarins or NBD, are to be used. The other suitable precursor
is the imidazobenzodiazepine desethylflumazenil (Ro15-3890), which has a free carboxyl group. A requirement to
obtain high affinity was not only the use of a small fluorophore, but also a spacer to optimize the distance
between the benzodiazepine and the fluorophore.
Besides the size of the fluorophore, its fluorescent characteristics are also important. To minimize
autofluorescence of matrix components, the excitation wavelength should preferably exceed 500 nm. However, the
fluorophores that fulfil this requirement also have a large molecular size, which makes them less suitable. Second,
the fluorescence properties of the labeled ligand should allow sensitive detection in aqueous media, since the
receptor assay can only be executed in these media. For this reason, the coumarin fluorophores have the
advantage over NBD, since the former have a three times higher fluorescence intensity than NBD in Tris-HCl
buffer (pH 7,4). Another important aspect of the fluorescent-labeled ligand is that after an eventual hydrolysis of
the labeled ligand, the resulting products have no affinity for the receptor.
From all these points, it can be concluded that the coumarin derivative Mmc-O-CO-(CH2)3-Ro15-3890 is the
fluorescent-labeled of first choice: It has a high affinity for the benzodiazepine receptor, the fluorophore has a
relative high fluorescence intensity in aqueous media and the resulting compounds after an eventual hydrolysis
have no affinity for the benzodiazepine receptor.
In Chapter 8, the development of a fluorescent receptor assay for benzodiazepines, using Mmc-O-CO-(CH2)3-Ro15-
3890 as labeled ligand is described.
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